GLENMARK LIFE SCIENCES
Quarterly Results Analysis [Sep2024]
GLENMARK LIFE SCIENCES Quarterly Results
Standalone | Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 Audited |
Dec2023 Audited |
Sep2023 Audited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹507 Cr | ₹589 Cr | ₹537 Cr | ₹573 Cr | ₹595 Cr | ₹578 Cr | ₹621 Cr | ₹541 Cr |
Expenses | ₹373 Cr | ₹429 Cr | ₹395 Cr | ₹400 Cr | ₹428 Cr | ₹385 Cr | ₹415 Cr | ₹395 Cr |
Operating Income | ₹134 Cr | ₹159 Cr | ₹141 Cr | ₹173 Cr | ₹167 Cr | ₹193 Cr | ₹206 Cr | ₹145 Cr |
Other Income | ₹9 Cr | ₹5 Cr | ₹3 Cr | ₹2 Cr | ₹5 Cr | ₹2 Cr | ₹3 Cr | ₹7 Cr |
Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
Depreciation | ₹15 Cr | ₹14 Cr | ₹15 Cr | ₹13 Cr | ₹13 Cr | ₹13 Cr | ₹12 Cr | ₹11 Cr |
Profit Before Tax | ₹127 Cr | ₹150 Cr | ₹130 Cr | ₹161 Cr | ₹159 Cr | ₹182 Cr | ₹198 Cr | ₹141 Cr |
Profit After Tax | ₹95 Cr | ₹111 Cr | ₹98 Cr | ₹119 Cr | ₹119 Cr | ₹135 Cr | ₹146 Cr | ₹105 Cr |
EPS | ₹7.78 | ₹9.10 | ₹7.99 | ₹9.69 | ₹9.69 | ₹11.05 | ₹11.95 | ₹8.57 |
Industry Peers & Returns | 1W | 1M | 1Y |
GLENMARK LIFE SCIENCES | -0.6% | 7% | 70.9% |
SUN PHARMACEUTICAL INDUSTRIES | -1.3% | -4.8% | 45% |
CIPLA | 2.1% | 3.8% | 24.5% |
DR REDDYS LABORATORIES | -0.6% | -5.7% | 5.7% |
ZYDUS LIFESCIENCES | 0.1% | -3.6% | 48.2% |
DIVIS LABORATORIES | 0.5% | 6.4% | 58.2% |
MANKIND PHARMA | -1.9% | 1.4% | 33.8% |
TORRENT PHARMACEUTICALS | 1.8% | 3.6% | 53.3% |
LUPIN | -2.7% | -7.1% | 60.8% |
GLENMARK LIFE SCIENCES Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -13.89 % |
Y-o-Y | -14.86 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Sep2024 | ₹507 Cr | -13.89 | |
Jun2024 | ₹589 Cr | 9.69 | |
Mar2024 | ₹537 Cr | -6.32 | |
Dec2023 | ₹573 Cr | -3.79 | |
Sep2023 | ₹595 Cr | 2.92 | |
Jun2023 | ₹578 Cr | -6.90 | |
Mar2023 | ₹621 Cr | 14.90 | |
Dec2022 | ₹541 Cr | - |
GLENMARK LIFE SCIENCES Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -15.75 % |
Y-o-Y | -19.59 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Sep2024 | ₹134 Cr | -15.75 | |
Jun2024 | ₹159 Cr | 12.75 | |
Mar2024 | ₹141 Cr | -18.03 | |
Dec2023 | ₹173 Cr | 3.27 | |
Sep2023 | ₹167 Cr | -13.50 | |
Jun2023 | ₹193 Cr | -6.43 | |
Mar2023 | ₹206 Cr | 41.92 | |
Dec2022 | ₹145 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -2.14 % |
Y-o-Y | -5.52 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Sep2024 | 26.51% | -2.14 | |
Jun2024 | 27.09% | 2.77 | |
Mar2024 | 26.36% | -12.48 | |
Dec2023 | 30.12% | 7.34 | |
Sep2023 | 28.06% | -15.96 | |
Jun2023 | 33.39% | 0.51 | |
Mar2023 | 33.22% | 23.49 | |
Dec2022 | 26.9% | - |
GLENMARK LIFE SCIENCES Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -14.50 % |
Y-o-Y | -19.73 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Sep2024 | ₹95 Cr | -14.50 | |
Jun2024 | ₹111 Cr | 13.83 | |
Mar2024 | ₹98 Cr | -17.54 | |
Dec2023 | ₹119 Cr | 0.02 | |
Sep2023 | ₹119 Cr | -12.34 | |
Jun2023 | ₹135 Cr | -7.45 | |
Mar2023 | ₹146 Cr | 39.40 | |
Dec2022 | ₹105 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -0.74 % |
Y-o-Y | -5.72 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Sep2024 | 18.8 % | -0.74 | |
Jun2024 | 18.94 % | 3.78 | |
Mar2024 | 18.25 % | -11.96 | |
Dec2023 | 20.73 % | 3.96 | |
Sep2023 | 19.94 % | -14.86 | |
Jun2023 | 23.42 % | -0.59 | |
Mar2023 | 23.56 % | 21.32 | |
Dec2022 | 19.42 % | - |
GLENMARK LIFE SCIENCES Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -14.51 % |
Y-o-Y | -19.71 % |
Quarters | EPS | % Change | |
---|---|---|---|
Sep2024 | ₹7.78 | -14.51 | |
Jun2024 | ₹9.1 | 13.89 | |
Mar2024 | ₹7.99 | -17.54 | |
Dec2023 | ₹9.69 | 0.00 | |
Sep2023 | ₹9.69 | -12.31 | |
Jun2023 | ₹11.05 | -7.53 | |
Mar2023 | ₹11.95 | 39.44 | |
Dec2022 | ₹8.57 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD